search
Back to results

Gracie Diet for Gastroesophageal Reflux Disease

Primary Purpose

Gastroesophageal Reflux, GERD

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Gracie Diet
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroesophageal Reflux focused on measuring GERD, Diet, Reflux

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 years or older at registration.
  • Patients with ongoing symptoms of GERD: heartburn (pyrosis) mid-sternal chest pain, regurgitation of fluid or food, development of esophageal inflammation that may lead to swallowing dysfunction, or extraesophageal manifestations (i.e. cough, bronchospasms, and hoarseness).
  • Use of one of the following PPI medications: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole or dexlansoprazole. And/or use of one of the following H2 blockers medications as well: famotidine, cimetidine, ranitidine or nizatidine.
  • Willing to comply with the Gracie diet regimen

Exclusion Criteria:

  • Age < than 18 years.
  • Patients unable to speak English.
  • Pregnancy or nursing.
  • Complicated oropharyngeal dysphagia or other condition with risk for aspiration from oral ingestion.
  • Exclusion of other causes of symptoms as mechanical gastrointestinal obstruction, Barrett's esophagus and cancer of the esophagus by standard radiographic or endoscopic test evidenced in the medical record chart.
  • A prior surgery of the upper gastrointestinal tract.
  • Failure to give informed consent.
  • Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study.

Sites / Locations

  • Johns Hopkins Bayview Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Gracie Diet

Arm Description

Patients will have a nutritional consultation and will follow the Gracie diet for a month.

Outcomes

Primary Outcome Measures

Change in University of California Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) score
The effect of the Gracie Diet in GERD symptoms by changes in the UCLA SCTC GIT 2.0 score. The UCLA-SCTC GIT 2.0 is a multi-item instrument that measures GI symptoms and their impact on health related quality of life. Includes 34 questions in 7 domains (reflux, distension, soilage, diarrhea, social function, emotional wellbeing and constipation) during a 7 day recall period. Each domain is weighted and scored, and a total score is then calculated.
Change in Patient Reported Outcomes Measurement Information System (PROMIS) scale score
The effect of the Gracie Diet in GERD symptoms by changes in the PROMIS Scale score. This questionnaire has items that measure the frequency, severity, impact, and bother of cardinal GERD symptoms, including heartburn and regurgitation, using a seven-day recall period. The questionnaire consists of 13 questions, and in each question, the answers are scored from 0 to 5.
Change in the Reflux Symptoms Index (RSI) score
The effect of the Gracie Diet in GERD symptoms by changes in the RSI score. The RSI is a nine-item questionnaire assessing symptom severity, and designed to assess the severity of symptoms related to laryngopharyngeal reflux. Normative data suggests that a RSI of greater than or equal to 13 is clinically significant. Therefore a RSI > 13 may be indicative of significant reflux disease.
Change in the Health-related Quality Of Life scale for GERD (GERD-HRQL) score
The effect of Gracie Diet in GERD symptoms by changes in the score of the GERD - HRQL. The GERD-HRQL was developed to survey symptomatic outcomes and therapeutic effects in patients with GERD. The scale has 11 items, which focus on heartburn symptoms, dysphagia, medication effects and the patient's present health condition. The GERD-HRQL takes approximately one minute to complete. Each item is scored from 0 to 5, with a higher score indicating a better QOL.
Change in the Gracie Diet adherence as assessed by a patient diary inventory
Assess adherence to diet through the use of a diary where the patient can track the food eaten during the day.
Change in GERD medication
The effect of Gracie Diet in medication intake through a review of the medication list, dose and intake frequency.

Secondary Outcome Measures

Change in Body Mass Index (BMI)
The effect of Gracie Diet in the BMI (kg/m^2). BMI is a person's weight in kilograms divided by the square of height in meters. The range values are Below 18.5 Underweight 18.5 - 24.9 Normal or Healthy Weight 25.0 - 29.9 Overweight 30.0 or higher Obese

Full Information

First Posted
April 20, 2020
Last Updated
March 14, 2023
Sponsor
Johns Hopkins University
search

1. Study Identification

Unique Protocol Identification Number
NCT04360252
Brief Title
Gracie Diet for Gastroesophageal Reflux Disease
Official Title
Gracie Diet for Gastroesophageal Reflux Disease
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 13, 2020 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
GERD, is a common and chronic world-wide disease. Cardinal symptoms of this condition are heartburn-regurgitation, and sometimes with extra-intestinal symptoms that can affect patients' quality of life. Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases. This class of medications is the most widely used for the management of GERD. H2 Receptor Antagonists (H2RAs) are another type of medication used to of uncomplicated GERD, gastric or duodenal ulcers, gastric hypersecretion, and for mild to infrequent heartburn or indigestion. H2RAs decrease gastric acid secretion by reversibly binding to histamine H2 receptors located on gastric parietal cells, thereby inhibiting the binding and action of the endogenous ligand histamine. Dietary modification is endorsed by the National Institutes of Health and the American College of Gastroenterology as a first-line therapy for patients with GERD. The Gracie Diet is thought to play an important role in the prevention of GERD. The concept behind this diet is that the consumption of proper food combinations promotes optimal health by preventing unhealthy chemical reactions in the digestive process such as fermentation and acidity. This diet describes the benefits of combining different foods together and the downsides of combining others. It provides guidance on avoiding specific foods and combinations of foods that may aggravate GERD, and adopting meal spacing habits to improve overall health outcomes. The idea is that such dietary changes support more efficient digestion and encourage healthier lifestyles (i.e. smoking cessation, elimination of alcohol intake, avoidance of soda consumption and desserts). This diet also supports the acquisition of healthy eating habits characterized by higher consumption of fruits, vegetables, and whole grains, and encourages a reduction in the intake of saturated fat, sodium, added sugars, and canned foods. Limiting beverage consumption of water or fresh coconut water between meals is also encouraged. In this pilot study, the investigators hypothesized that the Gracie diet it could be an alternative option to improve GERD symptoms in those patients who do not respond to standard doses of PPI and/or H2 receptor antagonists.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux, GERD
Keywords
GERD, Diet, Reflux

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Gracie Diet
Arm Type
Experimental
Arm Description
Patients will have a nutritional consultation and will follow the Gracie diet for a month.
Intervention Type
Other
Intervention Name(s)
Gracie Diet
Intervention Description
The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet. The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest.
Primary Outcome Measure Information:
Title
Change in University of California Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) score
Description
The effect of the Gracie Diet in GERD symptoms by changes in the UCLA SCTC GIT 2.0 score. The UCLA-SCTC GIT 2.0 is a multi-item instrument that measures GI symptoms and their impact on health related quality of life. Includes 34 questions in 7 domains (reflux, distension, soilage, diarrhea, social function, emotional wellbeing and constipation) during a 7 day recall period. Each domain is weighted and scored, and a total score is then calculated.
Time Frame
Baseline, week 2 and week 4
Title
Change in Patient Reported Outcomes Measurement Information System (PROMIS) scale score
Description
The effect of the Gracie Diet in GERD symptoms by changes in the PROMIS Scale score. This questionnaire has items that measure the frequency, severity, impact, and bother of cardinal GERD symptoms, including heartburn and regurgitation, using a seven-day recall period. The questionnaire consists of 13 questions, and in each question, the answers are scored from 0 to 5.
Time Frame
Baseline, week 2 and week 4
Title
Change in the Reflux Symptoms Index (RSI) score
Description
The effect of the Gracie Diet in GERD symptoms by changes in the RSI score. The RSI is a nine-item questionnaire assessing symptom severity, and designed to assess the severity of symptoms related to laryngopharyngeal reflux. Normative data suggests that a RSI of greater than or equal to 13 is clinically significant. Therefore a RSI > 13 may be indicative of significant reflux disease.
Time Frame
Baseline, week 2 and week 4
Title
Change in the Health-related Quality Of Life scale for GERD (GERD-HRQL) score
Description
The effect of Gracie Diet in GERD symptoms by changes in the score of the GERD - HRQL. The GERD-HRQL was developed to survey symptomatic outcomes and therapeutic effects in patients with GERD. The scale has 11 items, which focus on heartburn symptoms, dysphagia, medication effects and the patient's present health condition. The GERD-HRQL takes approximately one minute to complete. Each item is scored from 0 to 5, with a higher score indicating a better QOL.
Time Frame
Baseline, week 2 and week 4
Title
Change in the Gracie Diet adherence as assessed by a patient diary inventory
Description
Assess adherence to diet through the use of a diary where the patient can track the food eaten during the day.
Time Frame
Daily up to 4 weeks
Title
Change in GERD medication
Description
The effect of Gracie Diet in medication intake through a review of the medication list, dose and intake frequency.
Time Frame
Baseline, week 2 and week 4
Secondary Outcome Measure Information:
Title
Change in Body Mass Index (BMI)
Description
The effect of Gracie Diet in the BMI (kg/m^2). BMI is a person's weight in kilograms divided by the square of height in meters. The range values are Below 18.5 Underweight 18.5 - 24.9 Normal or Healthy Weight 25.0 - 29.9 Overweight 30.0 or higher Obese
Time Frame
Baseline, week 2 and week 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older at registration. Patients with ongoing symptoms of GERD: heartburn (pyrosis) mid-sternal chest pain, regurgitation of fluid or food, development of esophageal inflammation that may lead to swallowing dysfunction, or extraesophageal manifestations (i.e. cough, bronchospasms, and hoarseness). Use of one of the following PPI medications: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole or dexlansoprazole. And/or use of one of the following H2 blockers medications as well: famotidine, cimetidine, ranitidine or nizatidine. Willing to comply with the Gracie diet regimen Exclusion Criteria: Age < than 18 years. Patients unable to speak English. Pregnancy or nursing. Complicated oropharyngeal dysphagia or other condition with risk for aspiration from oral ingestion. Exclusion of other causes of symptoms as mechanical gastrointestinal obstruction, Barrett's esophagus and cancer of the esophagus by standard radiographic or endoscopic test evidenced in the medical record chart. A prior surgery of the upper gastrointestinal tract. Failure to give informed consent. Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert Bulat, MD
Phone
410-550-2060
Email
rbulat1@jhmi.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Bulat, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins Bayview Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Bulat, MD
Phone
410-550-2060
Email
rbulat1@jhmi.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Gracie Diet for Gastroesophageal Reflux Disease

We'll reach out to this number within 24 hrs